Introduction
Nogo has been proposed to be a major myelin-derived inhibitor of axon regeneration in the mammalian central nervous system (CNS). Three studies tested this hypothesis by assessing regeneration in various Nogo-deficient mice following spinal cord injury (Kim et al., 2003; Simonen et al., 2003; Zheng et al., 2003) , yet different regenerative responses were reported. In studies of a Nogo gene trap mutant, Kim et al. (2003) reported dramatically enhanced sprouting above the lesion, reflected by the presence of CST axons in ectopic locations (the lateral funiculus ipsilateral to the injection) in all (12/12) Nogo knockout mice. Evidence of striking long-distance regeneration was the presence of ectopic BDA-labeled axons more than 5 mm caudal to the injury in 7/11 Nogo knockout mice that received spinal cord injuries at 7.5-9 weeks of age. Three mice that underwent surgery at 11-14 weeks of age did not exhibit evidence of long-distance regeneration. The labeled axons in caudal segments seemed to be especially compelling evidence of robust but disorderly regeneration of the CST because labeled axons were present bilaterally in the lateral funiculus (an ectopic location).
In contrast, Simonen et al. (2003) reported increased sprouting near the lesion site in a Nogo-A-targeted knockout (in which Nogo-B expression was upregulated) and evidence for enhanced regeneration below the lesion in a subset (4/16) of mutants, although there was no statistically significant difference between knockout and controls. Our group found no statistically significant difference between Nogo-A,B (or Nogo-A,B,C) mutants and wildtype controls in the extent of CST sprouting above the lesion or regeneration past the lesion (Zheng et al., 2003) . One enigmatic finding was that ectopic axons similar to those reported by Kim et al. were observed in one control mouse (see Figure S2 in the Supplemental Data of Zheng et al., 2003) .
Possible reasons for the discrepant results have been discussed (Woolf, 2003) , but there has been no satisfactory explanation of the apparently robust regeneration in one study and modest or no enhanced regeneration in the others. Accordingly, we set out to perform a full replication of the experiments in the knockout line used in our study (Zheng et al., 2003) and the gene trap line used by Kim et al. (2003) , which were reported to exhibit striking regeneration. In the course of our studies, we discovered that axons in the white matter stain artifactually when BDA leaks into the cerebrospinal fluid (CSF) in the cerebral ventricle, producing a pattern of ectopic labeled axons that is remarkably similar to what was interpreted as massive sprouting/regeneration by Kim et al. In this report, we document the artifactual labeling, show that it occurs as a result of BDA entering the CSF, and demonstrate that the artifact may be avoided by delaying the tract tracing injections for 4 weeks after spinal cord lesions.
Results
In all three studies of Nogo knockout mice, regeneration was assessed following transection of the dorsal half of the spinal cord (a dorsal hemisection) at T8, which in mice interrupts descending CST axons while sparing white matter and gray matter in ventral portions of the spinal cord. Possible regeneration of cortico-spinal tract (CST) axons was then assessed by injecting biotinylated dextran amine (BDA) into the sensorimotor cortex. Importantly, all three studies used a similar, short-term protocol: the cortical BDA injection was made in the same operative procedure as the spinal cord lesion, and regeneration was assessed 2-3 weeks later.
In our replication experiment, we used the same protocol to assess possible CST regeneration in homozygous mutant and control (wild-type and heterozygotes). BDA was injected using the coordinates described in Zheng et al. (2003) (Kim et al. [2003] did not report their coordinates). One small procedural difference that turned out to be important was that, in our previous study (Zheng et al., 2003) , BDA was injected at a depth of 0.5 mm in the cortex, whereas in the repeat experiment we lowered the syringe below 0.5 mm and then withdrew to the final location. This was done to achieve greater accuracy because the cortex is frequently displaced slightly as the microsyringe is lowered. As discussed below, this had the unintended consequence that the syringe sometimes penetrated the ventricle.
In intact mice (that is, without spinal cord injuries), injections of BDA into the sensorimotor cortex produce robust labeling of dorsal main CST in the ventral part of the dorsal column and the dorsolateral CST in the dorsal part of the lateral column ( Figure 1A and Steward et al., 2004) . A few BDAlabeled axons are sometimes seen in the dorsal column and dorsal lateral funiculus ipsilateral to the injection representing an uncrossed component of CST axons that travel in the location of the main tracts. We have not seen evidence of a ventral CST in mice (that is, BDA-labeled longitudinal axons in the ventral column ipsilateral to the injection), although BDA-labeled collaterals can be seen extending from the gray matter into the ventral column. In addition to the longitudinal CST axons, BDA-labeled terminal arbors are present throughout the gray matter on the side contralateral to the injection (ipsilateral to the main descending tracts), and axon collaterals recross the midline to form sparse terminal arbors on the side ipsilateral to the injection.
In our repeat experiment, we were surprised to find a dramatic pattern of ectopic axonal labeling in both knockout and control mice comparable to the pattern seen in Nogo knockout mice by Kim et al. (2003) . Figures 1B-1C illustrate a heterozygous control in which this pattern was observed. Rostral to the lesion ( Figure 1B) , there are abundant BDA-labeled axons in ectopic locations in the lateral funiculus both ipsilateral and contralateral to the main tract. Below the lesion (Figure 1C) , ectopic axons are abundant in the lateral funiculus on both sides, whereas there were no BDA-labeled axons in either the main tract (the DCST) or the DLCST in caudal sections. This highly resembles the pattern that Kim et al. interpreted as robust sprouting/regeneration.
Above the injury, labeled axons were seen in ectopic locations in 4/6 wildtype mice, 9/12 heterozygotes, and 7/15 knockout mice; below the injury, ectopic axons were present in 3/6 wild-type mice, 5/12 heterozygotes, and 7/15 knockouts. Assessment of the subset of mice that did not exhibit ectopic labeled axons (2/6 wild-types, 3/12 heterozygotes, and 5/15 homozygous knockouts) revealed no other obvious indication of enhanced regeneration in the knockout mice compared to controls. It remains to be seen whether a more subtle regeneration phenotype can be detected in quantitative analyses using techniques that avoid the artifact we describe here.
BDA-labeled axons in ectopic locations had a distinctly different appearance from the bona fide labeled axons in the DCST and DLCST. First, they were larger, which is surprising if they actually were regenerated axons. Figure 2 illustrates this in a different case than shown in Figures 1A-1E . Second, ectopic axons had a ''hollow'' appearance, suggesting that labeling was associated with the outside of the axon or perhaps even the myelin sheath rather than the core of the axon. The hollow appearance can best be seen by focusing up and down in the microscope (see Movies S1 and S2 in the Supplemental Data available with this article online). Third, labeled axons in ectopic locations are not as strongly reflective in dark field illumination as the labeled axons in normal locations ( Figure S1 ). Nevertheless, the staining does indicate the presence of BDA, because when unstained sections are assessed for the presence of fluorescence from the mini-ruby that is conjugated to the BDA, the ectopic axons do show weak fluorescence (data not shown).
The ectopic axons described above were seen in experiments in which BDA injections were made immediately following spinal cord injuries. To explore whether the ectopic labeling was related to this timing, we examined cases from another ongoing experiment in which BDA injections were made 28 days after identical dorsal hemisection injuries. We examined 11 control mice in this experiment; none of the 11 exhibited ectopic axons, although CST axons in the normal tracts were heavily labeled. An example is illustrated in Figure 2D . The findings that a majority of mice had the artifactual BDA labeling in the short-term experiment, but that none did in this longer-term experiment, despite using an identical BDA-injection protocol, implies that the artifactual BDA labeling can be avoided by delaying the injection. The minimal delay required to avoid artifactual labeling remains to be defined, but a 4 week delay appears adequate and would be appropriate for documenting regeneration.
We were puzzled by two aspects of the results-the unusual appearance of the ectopic axons and the fact that the pattern of ectopic axonal labeling was seen when injections were made at the same time as the lesions, but not when injections were delayed. Accordingly, we began to suspect that there might be some artifact that accounted for the labeling of ectopic axons, and so we analyzed the cases carefully to try to identify a possible source of artifact. Three clues suggested that labeling might be artifactual. First, in addition to the BDAlabeled axonal retraction balls above the lesion, reflecting transected axons of the CST, some BDA-labeled axonal retraction balls were present caudally ( Figure 1D ). BDA-labeled retraction balls on axons that approach the lesion from below cannot be explained by transport along known pathways from the cerebral cortex. Second, BDA-labeled axons that passed the lesion in ectopic locations (the lateral funiculus) appeared straight and unbranched, whereas a tortuous trajectory is expected of an axon that has regenerated. A third clue came from inspection of the cortical injection sites, as we noticed clear evidence of BDA leakage into the cerebral ventricle in several cases. Figure 1E illustrates the injection site from the case shown in Figures 1A-1D . Heavy BDA labeling of cells in the ependymal layer reveals that BDA did leak into the ventricle in this case. These findings suggested the hypothesis that the labeling of axons in ectopic locations might be due to leakage of BDA into the CSF and uptake by damaged axons. To test this directly, five wild-type mice received spinal cord injuries followed in the same operative procedure by BDA injections directly into the cerebral ventricle and were allowed to survive for 17 days. Remarkably, 4/5 mice exhibited substantial numbers of BDAlabeled axons in ectopic locations in segments rostral to the injury (representative sections for all four are shown in Figures 3A-3D) . Interestingly, ectopic axons were more numerous on the side ipsilateral to the injection, which was also true of the ectopic axons described by Kim et al. Two of the five also exhibited BDAlabeled ectopic axons caudal to the injury (an example from one of these mice is shown in Figures 3E-3F) , despite the fact that there were no BDA-labeled axons in either the DCST or DLCST in the sections caudal to the lesions because the main tracts had been interrupted (data not shown). The pattern of ectopic labeling seen here was comparable to the pattern of ectopic labeling attributed to robust sprouting and regeneration by Kim et al. (2003) , who similarly saw labeling below the lesion, but only in ectopic locations, not the DCST. To further test the hypothesis that damaged axons at the lesion site take up BDA, another group of five mice received dorsal hemisection lesions and intraventricular BDA injections and were killed 3 days later. Three days is far too short a time for transport of BDA from the cortex, but if BDA is taken up by damaged axons at the lesion site, labeled axons should be seen near the lesion site. Indeed, 4/5 animals exhibited clear BDA-labeled axons and axonal retraction balls in ectopic locations. Moreover, labeling was seen only in segments of the axons within a few hundred micrometers of the lesion. Figures 3G and 3H show examples of these in cross-section and sagittalsection, respectively.
Discussion
Here we show that injecting BDA at the same time as a spinal cord injury, and carrying out injections in such a way that BDA leaks into the ventricles, produces remarkable artifactual labeling of axons in the injured spinal cord that is suggestive of robust regenerative growth. The artifact that we document here can explain the dramatic pattern of ectopic axonal labeling that seemed to be compelling evidence for robust regeneration in one line of Nogo knockout mice (Kim et al., 2003) . In our attempt to replicate their results using their mice and their protocol, we observed a similar pattern of dramatic labeling in a majority of animals, regardless of genotype, that appears to be due to leakage of BDA into the ventricles. The similarities in labeling patterns between the two studies are compelling: rostral to the lesion, massive labeling of axons outside the DCST and DLCST is observed in similar locations in their and our study; similarly, in transverse sections below the lesion site, massive labeling is seen in several animals in ectopic locations, but not in the location of the normal DCST.
The fact that this pattern of ectopic axonal labeling occurs in wild-type mice when BDA is injected into the ventricle certainly suggests the need to reanalyze CST regeneration in Nogo knockout mice under conditions where the chances of artifact are minimized. One can easily imagine how the likelihood of artifactual labeling may differ across genotypes, ages, or strains, for example, because of differences in maturation rate, cortical thickness, or differences in cell packing density, which could alter diffusion of BDA. Our results also raise questions about other studies that used the strategy of injecting BDA at the time of a spinal cord injury. These include one subset of studies involving injections of peptide inhibitors of Nogo ) and a recent study comparing regenerative responses in Nogo knockout mice on different genetic backgrounds (Dimou et al., 2006) .
We focus here on the artifactual labeling of large axons in ectopic locations, but other populations of axons may also be artifactually labeled, including small axon arbors in the gray matter. The absence of labeled ectopic axons in given preparations does not necessarily ensure the absence of artifactual labeling of other axonal populations. Thus, for future studies, the most prudent approach will be to carry out injections at some time after spinal cord injury. The minimal delay required remains to be defined.
Experimental Procedures Experimental Animals
Our repeat of the study by Kim et al. (2003) used 8-to 10-week-old Nogo knockout mice (the gene trap mutant that was generously provided by these authors) and littermate controls obtained by backcrossing homozygous knockout mice to C57BL/6 mice. Young adult (8-to 10-week-old) female mice of the C57BL/6 strain were used in the experiment that involved direct injections of BDA into the cerebral ventricle. Histological procedures were identical to those described in our previous study (Zheng et al., 2003) , except as noted above (for details, see the Supplemental Experimental Procedures).
To determine the pattern of labeling that results when BDA is present in the cerebrospinal fluid (CSF), five female C57BL/6 control mice received dorsal hemisection injuries as above, and then BDA was injected directly into the cerebral ventricle underlying the sensorimotor cortex. For this purpose, the Hamilton microsyringe was inserted to a depth of 2 mm at a point 1 mm lateral to bregma, and 0.5 ml of BDA was delivered. Mice were allowed to survive for 17 days following the spinal cord injuries/injections. A second group of five mice received intraventricular BDA injections and were allowed to survive for 3 days.
Histological methods were identical to our previous study (Zheng et al., 2003) . For detailed procedures, see the Supplemental Experimental Procedures.
Supplemental Data
The Supplemental Data for this article can be found online at http://www.neuron.org/cgi/ content/full/54/2/191/DC1/.
